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Figure 1 | Temporal course of serum inﬂammatory biomarkers—C-reactive protein (CRP) and interleukin (IL)-6—in relation to the
patient’s need for oxygen therapy. The timing of tocilizumab infusion and administration of dexamethasone is shown by the arrows.

cyclosporine. The patient was hydrated, and antibiotic prophylaxis was started (Table 1). Unfortunately, the patient’s
respiratory function further deteriorated, and laboratory
ﬁndings were suggestive of cytokine release syndrome with
remarkably elevated (431 pg/ml) serum interleukin-6 levels.
A single i.v. infusion of tocilizumab (8 mg/kg per d) was
attempted. Two days after, oxygen was no longer required
(Figure 1). The patient was discharged home and
completely recovered from acute kidney injury.
Early detection of cytokine release syndrome biomarkers
is recommended and should prompt anti-inﬂammatory
interventions. Larger studies are needed to conﬁrm the
utility and safety of interleukin-6 inhibition combined
with dexamethasone in kidney transplant recipients with
COVID-19.
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Thrombotic
microangiopathy
in a patient with COVID-19
To the editor: We describe a patient with coronavirus disease 2019 (COVID-19) and clinically signiﬁcant kidney
biopsy-proven thrombotic microangiopathy.
A 69-year-old Caucasian female with a past medical history of asthma presented to the emergency department with
productive cough, fever, and shortness of breath of 2 weeks’
duration. In the emergency room, she was afebrile, with a
respiratory rate of 22 breaths per minute, and oxygen saturation of 89% on room air. Initial laboratory tests showed a
normal white blood cell count, hemoglobin level, and platelet
count. Inﬂammatory lab parameters were elevated (Table 1).
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection was conﬁrmed in the patient by reversetranscriptase polymerase chain reaction assay or serologic
testing at our center. A chest X-ray showed bilateral diffuse
patchy opacities.
The patient was admitted, and treatment with hydroxychloroquine, low-molecular-weight heparin, and oxygen was
initiated. Over the next several days, she received anakinra
and tocilizumab (dosages and details are given in Table 1). On
day 12, the patient’s labs demonstrated down-trending
platelets, hemoglobin, and worsening kidney function.
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Table 1 | Chronological treatment and laboratory data

Treatment given
Hemoglobin (11.5–15.5 g/dl)
Platelets (150–400 K/ul)
Serum creatinine, mg/dl
Fibrinogen (350–510 mg/dl)
D-dimer (<229 ng/ml DDU)
ADAMTS 13 activity level (>66.8%)
Alkaline phosphatase (40–120 U/l)
AST (10–40 U/l)
ALT (10–45 U/l)
LDH (50–242 U/l)
C-reactive protein (0–0.40 mg/dl)
Hep- PF 4 AB result (0.0–0.9 U/ml)
Hep- PF 4 AB interpretation
Schistocytes in smear
Haptoglobin (34–200 mg/dl)

Day 1

Day 7

Day 16

Day 17

Day 18

Hydroxychloroquine/
low-molecular-weight
heparin

Anakinra &
tocilizumab

Convalescent
plasma

Intubation

Dialysis
started

13
203
0.72

11.5
142
0.75

12.9
85
0.57

11.8
14
2.06
62

118
44
30

292
63
27
1073
6.85
<0.6
Negative

296
316
97

411
137
70
38
459
10.35

2.46

Day 19

Day 20

Day 21

Kidney
biopsy

Eculizumab

8.0
97
2.49
159
6068
43.2
194
404
146
3518
18.54

8.3
37
4.07
128
14,568

8.6
21
On dialysis
117
12,193

6.9
27
On dialysis
166
5927

212
254
239
5130
20.73

204
173
230
5183
13.61

294
148
165
4707
8.02

Present
<20

Present
<20

ADAMTS 13, disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hep,
heparin; LDH, lactate dehydrogenase; PF, endogenous protein platelet factor 4.
Medication dosages: anakinra 100 mg q6  8 doses; tocilizumab 400 mg i.v.  2 doses; eculizumab 900 mg i.v.—1 dose was able to be given (patient expired).

There was concern for microangiopathic hemolytic
anemia. Due to worsening hypoxemia, the patient
received convalescent plasma treatment as part of an
expanded access trial. On day 17, the patient was
intubated due to worsening respiratory failure. In
addition, the patient developed hemolysis (presence of
schistocytes, undetectable haptoglobin levels, high lactate
dehydrogenase level). Urinalysis showed hematuria, large
blood, 30–40 red blood cells/high-power ﬁeld, and 1.4 g
of protein. The patient’s kidney function worsened,
requiring initiation of continuous renal replacement
therapy. On day 20, the patient underwent a kidney
biopsy
that
revealed
severe
acute
thrombotic
microangiopathy with cortical necrosis (Figure 1).
Although beta 2 glycoprotein-1 IgM levels were elevated,
other laboratory and clinical features of antiphospholipid
antibody were absent (Table 2). The disintegrin and
metalloproteinase with a thrombospondin type 1 motif,
member 13 (ADAMTS13) level was not low. Complement
3 and 4 were in the normal range. Heparin-induced
antibody testing was negative. Coagulation parameters
were normal. A kidney sonogram was negative for renal
vein thrombosis and arterial clots. The patient did not
have any other systemic ﬁndings of macro thrombi.
Subsequent detailed complement testing revealed a low
factor H complement antigen, and elevated plasma CBb
complement and plasma SC5b-9 complement levels,
suggesting an activation of the alternative complement
pathway (Table 2). Genetic testing was not performed.
Given clinical instability, plasma exchange was not
performed. Instead, the patient was given a single dose of
eculizumab at 900 mg on day 21. Unfortunately, the
patient expired on day 23 in the setting of worsening shock.
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Coagulopathy associated with SARS-CoV-2 has been
widely reported.1,2 The profound hypoxia, inﬂammation, and
disseminated intravascular coagulation have all been
implicated as potential causes.2 There has also been a report
of
coagulopathy
secondary
to
development
of
antiphospholipid antibodies.3 Our patient had no evidence
of disseminated intravascular coagulation. Although we
cannot completely rule out antiphospholipid antibody
syndrome, it is less likely to have played a role in this case,
as there was no prior history of autoimmunity and no
other current stigmata of evolving connective tissue disease,
such as lupus, or antiphospholipid syndrome in other body
systems. Transient elevation of both beta-2 glycoprotein-1
IgG and IgM can be seen in the setting of infections and
drug exposures.4 Ideally, a conﬁrmation of autoantibodies is
needed at 12 weeks, which was not possible to do in this
case. Collapsing glomerulopathy associated with SARS-CoV2 has now been reported from several centers as the ﬁrst
described glomerular pathology in this setting.5,6 To our
knowledge, there have been no published cases of SARSCoV-2–associated systemic thrombotic microangiopathy. We
report the ﬁrst case of thrombotic microangiopathy
associated with SARS-CoV-2, with presence of diffuse
cortical necrosis and widespread microthrombi in the
kidney biopsy. It is not clear if the virus played a direct
pathogenic role or unmasked a latent complement defect
(as noted in our complement testing) leading to widespread
endothelial damage and micro thrombi.7
Acute kidney injury is not uncommon in patients with
COVID-19.8 Causes of acute kidney injury can range from prerenal azotemia, to acute tubular injury, to collapsing
glomerulopathy.5,6,9 Physicians treating patients with COVID19 should keep microangiopathic disease in the differential
Kidney International (2020) 98, 505–516
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Figure 1 | Kidney biopsy ﬁndings. (a) Kidney parenchyma reveals diffuse coagulative cortical necrosis, with widespread glomerular thrombi
(periodic acid–Schiff stain, original magniﬁcation 200). (b) Glomerulus with multiple microthrombi in upper right aspect of the image and
extensive coagulative necrosis of proximal tubules with ghost cells and nonviable nuclei (hematoxylin and eosin stain, original
magniﬁcation 200). (c) A thrombosed glomerulus with a large thrombus in the arteriole and vascular pole (Jones methenamine silver stain,
original magniﬁcation 400). (d) Electron micrograph with extensive crosslinked ﬁbrin deposits in capillary lumens and partially denuded
capillary due to ischemia and necrosis (original magniﬁcation 4000). To optimize viewing of this image, please see the online version of this
article at www.kidney-international.org.

diagnosis when systemic ﬁndings of hemolysis are present
along with thrombocytopenia and acute kidney injury.
Earlier diagnosis could perhaps lead to prompt treatment
with plasma exchange or complement pathway inhibitors.

ACKNOWLEDGMENTS

The authors acknowledge the Northwell Covid-19 Research
consortium.
The Northwell Health Institutional Review Board approved this
case as minimal-risk research using data collected for routine clinical
practice and waived the requirement for informed consent.

DISCLOSURE

KDJ serves as a consultant for Astex Pharmaceuticals and Natera. All
the other authors declared no competing interests.

Table 2 | Antiphospholipid panel and complement panel
Comprehensive complement testing with results and reference
ranges
Serum complement total—56U/ml (30–75)
Serum complement C3—105 mg/dl (75–175)
Serum complement C4—26 mg/dl (14–40)
Serum factor B complement antigen—28 mg/dl (15.2–42.3)
Serum factor H complement antigen—22 mg/dl (23.6–43.1)
Plasma C4d complement—2.3 mcg/ml (<9.9)
Plasma CBb complement—4.4 mcg/ml (<1.7)
Plasma SC5b-9 complement—875 ng/ml (<251)
Antiphospholipid antibody testing with results and reference ranges
Anticardiolipin IgG—13.6 GPL (0–12.5)
Anticardiolipin IgM—12.5 MPL (0–12.5)
Anticardiolipin IgA—6.7 APL (0–12.5)
Beta 2 glycoprotein—1 IgG—<5 SGU (<20)
Beta 2 glycoprotein—1 IgM—68.6 SMU (<20)
Beta 2 glycoprotein—1 IgA—8 SAU (<20)
APL, A phospholipids units; GPL, G phospholipids units; MPL, M phospholipids units;
SAU, standard IgA aB2G2P1 unit; SGU, standard IgG aB2GPI unit; SMU, standard IgM
aB2GPI unit.
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publication, 2020). Our data are also in line with the absence
of SARS RNA in efﬂuents from PD patients with SARS
infection.3
The opposite results for both observations argue for performing a SARS-CoV-2 culture to conﬁrm PD efﬂuent contagiousness before imposing speciﬁc procedures in PD patients.
1. Vischini G, D’Alonzo S, Grandaliano G, D’Ascenzo FM. SARS-CoV-2 in the
peritoneal waste in a patient treated with peritoneal dialysis. Kidney Int.
2020;98:237–238.
2. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of
clinical specimens. JAMA. 2020;323:1843–1844.
3. Kwan BC-H, Leung C-B, Szeto C-C, et al. Severe acute respiratory syndrome
in dialysis patients. J Am Soc Nephrol. 2004;15:1883–1888.
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Letter regarding “SARS-CoV-2
in the peritoneal waste in a
patient treated with peritoneal
dialysis”
To the editor: We read with interest the letter from Vischini
et al. about the presence of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) in the peritoneal efﬂuent of a
peritoneal dialysis (PD) patient.1 Coronavirus transmission
occurs primarily via respiratory droplets, and it has been
found inconsistently in body secretions and excretions.2 SARSCoV-2 virion is 60–140 nanometers and could theoretically
enter the peritoneal cavity via hematogenous diffusion or
through the PD catheter after touch contamination.
This observation of Vischini et al. if conﬁrmed, is
important for daily clinical care of PD patients and handling
of efﬂuents. However, they found positive polymerase chain
reaction tests in PD efﬂuents in their patient 1 month after
the ﬁrst symptoms, calling into question whether the virus
itself was present or whether it was just noncontagious RNA
fragments. In our experience with serial PD efﬂuent samplings from 3 PD patients with mild to moderate active
coronavirus disease 2019 (COVID-19), we found results
discordant with those of Vischini et al. We used quantitative
reverse transcription polymerase chain reaction analysis based
on the highly speciﬁc RdRp gene and E gene, in 2 independent
laboratories. Although nasopharyngeal swabs obtained at
admission showed high viral load in all 3 patients (cycle
threshold value <30), decreasing during hospitalization, none
of the 11 PD efﬂuent samplings at days 0–3–4–7 taken after a
12-hour dwell time tested positive, even after dialysate
centrifugation. A blood sample was positive in only one patient (A. Candellier, A. Scohy, N. Gillet, et al., submitted for
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Kidney transplantation
trends in South Korea
during the COVID-19 pandemic
To the editor: We read with interest the article by Banerjee
et al.1 reporting 7 cases of coronavirus disease 2019 (COVID19) in kidney transplant recipients. Banerjee et al.1 raised
concerns about increased susceptibility to COVID-19
infection during the postoperative period; however, the
impact of immunosuppression on susceptibility to COVID19 remains unknown. Recent data on clinical outcomes of
COVID-19 infection in kidney transplant patients are
conﬂicting.2 Furthermore, some preliminary reports suggest
the reduced immune response due to immunosuppression
may provide a protective effect against severe COVID-19.3
South Korea was one of the earliest countries to experience
the COVID-19 outbreak, quickly becoming the country with
the second highest number of COVID-19 infections after
China. In response, South Korea carried out extensive virus
testing and contact tracing. In cooperation with national-level
efforts, most transplant programs adopted universal donor
and recipient screening using reverse transcriptase polymerase chain reaction, in accordance with the Korean Transplantation Society recommendation. Thus, national kidney
transplant activities in South Korea remained stable for both
living and deceased donor transplantation compared with the
same period during the previous year (Table 1).
During these unprecedented times, little is known about
the safety of kidney transplantation. However, delaying or
halting of kidney transplantation is not a safe option for
patients with end-stage renal disease. Because they still
Kidney International (2020) 98, 505–516

